The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems
Authors:
Open Access
- 8 June 2006
- journal article
- review article
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 19 (2) , 139-148
Abstract
Phosphodiesterase-5 (PDE-5) inhibitors selectively inhibit PDE-5 enzymes that are present in various tissues like penile tissue, platelets, vascular, and smooth muscle tissue. The drug's actions on these tissues have lead to the successful therapeutic use in patients suffering from conditions such as erectile dysfunction (ED) and pulmonary hypertension. PDE-5 inhibitors (PDE-5i) act on the erectile tissue causing penile smooth muscle relaxation and vasodilatation leading to penile erection. In addition, in particular when used in conjunction with prostaglandin inhibitors, PDE-5i cause vasodilatation in pulmonary vasculature hence decreasing both the pulmonary arterial pressure and resistance. PDE-5i have also shown to mildly decrease blood pressure, increase cardiac index, and increase coronary blood flow in experimental animals as well as in human studies. The Food and Drug Administration (FDA) has approved three PDE-5i for the treatment of ED: sildenafil (Viagra), vardenafil (Levitra), and tadalafil (Cialis) and one for pulmonary hypertension: sildenafil (Revatio). These agents are highly selective for PDE-5 enzymes as compared to other subclasses of PDE enzymes and have the almost identical pharmacological action but slightly different pharmacokinetics. Only little data exist about long-term use of PDE-5i and their effects on different organ system. This paper reviews the current information available on chronic PDE-5 inhibitor use.Keywords
This publication has 78 references indexed in Scilit:
- Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathyInternational Journal Of Clinical Practice, 2006
- Effects of long‐term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's diseaseBJU International, 2006
- Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2004
- Long-Term Treatment With Oral Sildenafil Is Safe and Improves Functional Capacity and Hemodynamics in Patients With Pulmonary Arterial HypertensionCirculation, 2003
- Effect of sildenafil (Viagra®) on cerebral blood flow velocity: a pilot studyPsychiatry Research: Neuroimaging, 2003
- Sildenafil citrate does not affect cardiac contractility in human or dog heartCurrent Medical Research and Opinion, 2003
- The effects of steady‐state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteersBritish Journal of Clinical Pharmacology, 2002
- The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteersBritish Journal of Clinical Pharmacology, 2002
- Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5'-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta.Journal of Clinical Investigation, 1987
- Paradoxical Vasoconstriction Induced by Acetylcholine in Atherosclerotic Coronary ArteriesNew England Journal of Medicine, 1986